Telix initiates dosing in OPTIMAL-e trial, advancing earlier-stage prostate cancer therapy with TLX597-Tx
Executive summary: Telix Pharmaceuticals and St Vincent’s Hospital dosed the first patients with TLX597-Tx in the OPTIMAL-e trial for earlier-stage prostate cancer. The trial initiation advances Telix’s radiopharmaceutical pipeline and could lead to a new treatment option for prostate cancer patients.
Who is involved: Telix Pharmaceuticals (ASX:TLX, NASDAQ:TLX), St Vincent’s Hospital (Melbourne), and the enrolled patients in the OPTIMAL-e trial.
Likely next: Continued patient enrollment, safety monitoring, and interim efficacy readout are expected later in 2026 or 2027.
Telix Pharmaceuticals and St Vincent’s Hospital have administered the first doses of the investigational radiopharmaceutical TLX597-Tx to patients in the OPTIMAL-e trial, targeting earlier-stage prostate cancer. This milestone marks the start of clinical evaluation for a potential new therapeutic option in Telix’s oncology pipeline. The trial’s progress will be closely watched for safety and efficacy data that could inform future regulatory submissions.
Timeline
- — First Patients Dosed in OPTIMAL-e Trial for Earlier Stage Prostate Cancer (GlobeNewswire)
- — UNIVERSAL HEALTH SERVICES, INC. ANNOUNCES DIVIDEND (PR Newswire)
- — Certara to Report Second Quarter 2026 Financial Results on August 4th, 2026 (GlobeNewswire)
Sources
- First Patients Dosed in OPTIMAL-e Trial for Earlier Stage Prostate Cancer — GlobeNewswire
- Certara to Report Second Quarter 2026 Financial Results on August 4th, 2026 — GlobeNewswire
- UNIVERSAL HEALTH SERVICES, INC. ANNOUNCES DIVIDEND — PR Newswire